46 research outputs found
Table S12 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Table S12: [89Zr]Zr-DFO-IgG %IA/Organ in the RPMI8226 subcutaneous xenograft models.</p
Table S21 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Table S21: [18F]-FDG %IA/g in the ANBL6 subcutaneous xenograft models.</p
Table S2 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Table S2: %IA/Organ of [89Zr]Zr-DFO-YS5 in subcutaneous MM.1S tumor model.</p
Table S23 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Table S23: [89Zr]Zr-DFO-YS5 %IA/g in the MM.1S systemic tumor model.</p
Table S29 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Table S29: [89Zr]Zr-DFO-YS5 %IA/g in the RPMI8266 systemic tumor model.</p
Table S18 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Table S18: [18F]-FDG %IA/Organ in the MM.1S subcutaneous xenograft model.</p
Figure S5 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Figure S5: Targeted radioligand therapy with [225Ac]Ac-DOTA-YS5 demonstrates high treatment efficacy in the MM.1S subcutaneous MM model.</p
Table S5 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Table S5: Biodistribution analysis %IA/g of [89Zr]Zr-DFO-IgG (non-specific) in subcutaneous MM.1S tumor model.</p
Supplementary Methods 1 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Supplementary Methods</p
Figure S2 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Figure S2: Regulation of CD46 expression in multiple myeloma.</p